AQR Capital Management LLC Takes $67,000 Position in Protalix BioTherapeutics, Inc. (NYSE:PLX)

AQR Capital Management LLC bought a new stake in Protalix BioTherapeutics, Inc. (NYSE:PLX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 57,106 shares of the company’s stock, valued at approximately $67,000. AQR Capital Management LLC owned 0.08% of Protalix BioTherapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in PLX. Virtu Financial LLC acquired a new stake in shares of Protalix BioTherapeutics in the 1st quarter valued at $198,000. Squarepoint Ops LLC grew its stake in shares of Protalix BioTherapeutics by 673.3% during the second quarter. Squarepoint Ops LLC now owns 137,764 shares of the company’s stock worth $161,000 after purchasing an additional 119,949 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Protalix BioTherapeutics during the second quarter worth $80,000. Ground Swell Capital LLC acquired a new stake in shares of Protalix BioTherapeutics during the second quarter worth $73,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Protalix BioTherapeutics during the second quarter worth $37,000. 16.53% of the stock is owned by institutional investors and hedge funds.

Protalix BioTherapeutics Stock Down 0.5 %

Shares of Protalix BioTherapeutics stock opened at $1.09 on Friday. Protalix BioTherapeutics, Inc. has a 12 month low of $0.82 and a 12 month high of $1.90. The business has a fifty day simple moving average of $1.02 and a 200 day simple moving average of $1.11. The stock has a market cap of $79.79 million, a PE ratio of -5.43 and a beta of 0.70.

Protalix BioTherapeutics (NYSE:PLX) last posted its earnings results on Wednesday, August 14th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.05). The business had revenue of $13.47 million for the quarter, compared to the consensus estimate of $12.50 million. Protalix BioTherapeutics had a negative return on equity of 45.15% and a negative net margin of 38.62%. During the same quarter in the prior year, the firm posted ($0.07) earnings per share. Analysts expect that Protalix BioTherapeutics, Inc. will post 0.06 EPS for the current fiscal year.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.